Hims & Hers Health (HIMS) stock
NYSE
As of the Nov 17, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $4.11B
- As of Nov 17, 2026
- P/E
- -21.54x
- Trailing twelve months
- P/B
- 11.59x
- Latest reported equity
- P/S
- 1.43x
- Trailing twelve months
- ROE
- -53.8%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
- Market cap
- $4.11B
- As of Nov 17, 2026
- P/E
- -21.54x
- Trailing twelve months
- P/B
- 11.59x
- Latest reported equity
- P/S
- 1.43x
- Trailing twelve months
- ROE
- -53.8%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-21.54x
Net loss — not comparable
P/B
11.59x
P/S
1.43x
Earnings and dividend metrics▾
Earnings
EPS
—
Earnings per share
BPS
—
Book value per share
ROE
-53.8%
Return on equity
- ROE — shareholder equity shrank by 53.8% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 48.6% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $599M+48.6%
$402M
Jul–Sep '24
$599M
Jul–Sep '25
$890M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 9, 2026.
- Earnings per share decreased 333.3% from the same quarter a year earlier.
- Revenue increased 48.6% from the same quarter a year earlier.
- Operating income decreased 650.0% from the same quarter a year earlier.
- Net income decreased 306.2% from the same quarter a year earlier.
Filed Nov 9, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Elshenawy MohamedCTO · Nov 13, 2026Shares withheld for taxes95,798 shares · $1.9MAvg. price $19.73278,044 shares held after
- Dudum AndrewChief Executive Officer · Nov 13, 2026Shares withheld for taxes78,857 shares · $1.6MAvg. price $19.731,109,310 shares held after
- Chi MichaelChief Operating Officer · Nov 13, 2026Shares withheld for taxes38,581 shares · $761KAvg. price $19.73487,848 shares held after
- Okupe OluyemiChief Financial Officer · Nov 13, 2026Shares withheld for taxes36,437 shares · $719KAvg. price $19.73269,706 shares held after
- Boughton SoleilChief Legal Officer · Nov 13, 2026Shares withheld for taxes21,500 shares · $424KAvg. price $19.73314,648 shares held after
- Autor Deborah M.Chief Policy Officer · Nov 13, 2026Shares withheld for taxes16,146 shares · $319KAvg. price $19.7372,789 shares held after
- Carroll Patrick HarrisonChief Medical Officer · Nov 13, 2026Shares withheld for taxes10,200 shares · $201KAvg. price $19.73213,574 shares held after
- Okupe OluyemiChief Financial Officer · Nov 13, 2026Option exercise71,616 shares306,143 shares held after
- Boughton SoleilChief Legal Officer · Nov 13, 2026Option exercise42,262 shares336,148 shares held after
- Chi MichaelChief Operating Officer · Nov 13, 2026Option exercise69,769 shares526,429 shares held after
- Payne Christopher DDirector · Nov 13, 2026Option exercise810 shares35,673 shares held after
- Dudum AndrewChief Executive Officer · Nov 13, 2026Option exercise154,990 shares1,188,167 shares held after
- WELLS DAVID BDirector · Nov 13, 2026Option exercise1,051 shares230,859 shares held after
- Elshenawy MohamedCTO · Nov 13, 2026Option exercise188,286 shares373,842 shares held after
- Autor Deborah M.Chief Policy Officer · Nov 13, 2026Option exercise39,974 shares88,935 shares held after
- Carroll Patrick HarrisonChief Medical Officer · Nov 13, 2026Option exercise25,927 shares223,774 shares held after
- Boughton SoleilChief Legal Officer · Oct 28, 2026Open-market sale3,462 shares · $96KAvg. price $27.6293,886 shares held after
- Boughton SoleilChief Legal Officer · Oct 14, 2026Open-market sale3,461 shares · $101KAvg. price $29.06297,348 shares held after
- Okupe OluyemiChief Financial Officer · Oct 1, 2026Open-market sale2,000 shares · $59KAvg. price $29.7234,527 shares held after
- Boughton SoleilChief Legal Officer · Sep 30, 2026Open-market sale3,461 shares · $101KAvg. price $29.17300,809 shares held after
- Okupe OluyemiChief Financial Officer · Sep 22, 2026Open-market sale29,277 shares · $877KAvg. price $29.95236,527 shares held after
- Okupe OluyemiChief Financial Officer · Sep 22, 2026Option exercise14,000 shares · $70KAvg. price $5.01265,804 shares held after
- Okupe OluyemiChief Financial Officer · Sep 17, 2026Open-market sale12,313 shares · $355KAvg. price $28.82251,804 shares held after
- Boughton SoleilChief Legal Officer · Sep 16, 2026Open-market sale6,236 shares · $174KAvg. price $27.86304,270 shares held after
- Chi MichaelChief Operating Officer · Sep 15, 2026Open-market sale14,027 shares · $398KAvg. price $28.39456,660 shares held after
- Elshenawy MohamedCTO · Sep 15, 2026Open-market sale7,954 shares · $226KAvg. price $28.39185,556 shares held after
- Boughton SoleilChief Legal Officer · Sep 2, 2026Open-market sale3,458 shares · $98KAvg. price $28.33310,506 shares held after
- Dudum AndrewChief Executive Officer · Aug 27, 2026Other977,566 shares · $0Avg. price $0103,406 shares held after
- Dudum AndrewChief Executive Officer · Aug 25, 2026Gift463,289 shares · $0Avg. price $00 shares held after
- Boughton SoleilChief Legal Officer · Aug 19, 2026Open-market sale25,111 shares · $692KAvg. price $27.55313,964 shares held after
- Okupe OluyemiChief Financial Officer · Aug 19, 2026Open-market sale4,938 shares · $148KAvg. price $29.9942264,117 shares held after
- Okupe OluyemiChief Financial Officer · Aug 19, 2026Option exercise4,938 shares · $25KAvg. price $5.01269,055 shares held after
- Autor Deborah M.Chief Policy Officer · Aug 18, 2026Open-market sale16,773 shares · $467KAvg. price $27.8548,961 shares held after
- Okupe OluyemiChief Financial Officer · Aug 17, 2026Open-market sale9,388 shares · $262KAvg. price $27.8869264,117 shares held after
- Okupe OluyemiChief Financial Officer · Aug 17, 2026Option exercise9,388 shares · $47KAvg. price $5.01273,505 shares held after
- Elshenawy MohamedCTO · Aug 14, 2026Shares withheld for taxes95,798 shares · $2.7MAvg. price $28.15193,510 shares held after
- Dudum AndrewChief Executive Officer · Aug 14, 2026Shares withheld for taxes78,859 shares · $2.2MAvg. price $28.151,033,177 shares held after
- Chi MichaelChief Operating Officer · Aug 14, 2026Shares withheld for taxes47,702 shares · $1.3MAvg. price $28.15470,687 shares held after
- Okupe OluyemiChief Financial Officer · Aug 14, 2026Shares withheld for taxes36,437 shares · $1.0MAvg. price $28.15264,117 shares held after
- Boughton SoleilChief Legal Officer · Aug 14, 2026Shares withheld for taxes21,500 shares · $605KAvg. price $28.15339,075 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Hims & Hers Health (HIMS) stock information
NYSE
Hims & Hers Health (HIMS) is listed on NYSE. Its market capitalization is about $4.1B. On trailing-twelve-month earnings the P/E ratio is -21.54, and the P/B ratio is 11.59. Return on equity is -53.8%. These figures are computed in-house from official filings and are reference information only.
Hims & Hers Health — frequently asked questions
- What is the P/E ratio of Hims & Hers Health (HIMS)?
- On a trailing-twelve-month basis, HIMS trades at a P/E ratio of -21.54. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Hims & Hers Health?
- HIMS has a market capitalization of about $4.1B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.